BTIG initiated coverage of iCAD (NASDAQ:ICAD) with a “buy” rating and a price target of $25. The stock closed at $19.35 on March 22. iCAD is a medical technology company focused on cancer care, offering both cutting...
Cantor Fitzgerald launched coverage of Eledon Pharmaceuticals (NASDAQ:ELDN) with an “overweight” rating and $25 price target. The stock closed at $13.65 on March 22. Eledon is focused on developing AT-1501, which is an...
H.C. Wainwright launched coverage of MiMedx Group (NASDAQ:MDXG) with a “buy” rating and $20 price target. The stock closed at $8.81 on March 18. MiMedx is a wound care industry leader commercializing placental...
William Blair downgraded Acutus Medical (NASDAQ:AFIB) to “market perform,” saying “early-stage growing pains lead to lower than expected guidance.” The stock closed at $16.83, down $2.23, on March 18. Analyst Margaret...
SVB Leerink launched coverage of Merus NV (NASDAQ:MRUS) with an “outperform” rating and $33 price target. The stock closed at $22.04 on March 15. Merus is focused on developing novel bispecific and trispecific...
Maxim Group initiated coverage of Oncorus (NASDAQ:ONCR) with a “buy” rating and price target of $35. The stock closed at $16.39 on March 15. Oncorus is developing oncolytic viral (OV) immunotherapies for solid tumors...
SVB Leerink upgraded Solid Biosciences (NASDAQ:SLDB) to “outperform” from “market perform” and raised its price target to $15 from $3, citing the first functional data for the company’s microdystrophin gene...
Canaccord Genuity raised its price target for TransMedics Group (NASDAQ:TMDX) to $79 from $46, saying the company has the “technology that will become the standard of care for organ transplant and in the process...
BTIG initiated coverage of Seelos Therapeutics (NASDAQ:SEEL) with a “buy” rating and $14 price target. The stock closed at $3.04 on March 11. Seelos’ lead clinical candidate, SLS-002, is an intranasally delivered...
William Blair upgraded Selecta Biosciences (NASDAQ:SELB) to “outperform,” citing multiple upcoming positive risk/reward catalysts for the company. The stock closed at $3.90 on March 11. The company’s ImmTOR platform...
SVB Leerink launched coverage of Aldeyra Therapeutics (NASDAQ:ALDX) with an “outperform” rating and $22 price target. The stock closed at $12.07 on March 11. Two of the company’s lead investigational compounds...
Maxim Group raised its price target for Entera Bio (NASDAQ:ENTX) to $10 from $5, citing updated data from an ongoing Phase 2 trial of oral parathyroid hormone candidate, EB613, in osteoporosis. At midday on March 11...
Maxim Group launched coverage of MediciNova (NASDAQ:MNOV) with a “buy” rating and $15 price target. The stock closed at $5.68 on March 9. MediciNova is developing MN-166 for neurodegenerative diseases, glioblastoma...
Cantor Fitzgerald initiated coverage of Auxly Cannabis Group (TSXV:XLY) with an “overweight” rating and price target of 85 cents (Canadian). The stock closed at 36 cents on March 9. Auxly is the number one player in...
Maxim Group launched coverage of Panbela Therapeutics (NASDAQ:PBLA) with a “buy” rating and $8 price target. The stock closed at $4.17 on March 9. The company’s polyamine metabolic inhibitor drug candidate, SBP...
Cantor Fitzgerald launched coverage of NexImmune (NASDAQ:NEXI) with an “overweight” rating and price target of $35. The stock closed at $20.63 on March 8. NexImmune is developing a novel approach in cancer immunotherapy...
BTIG initiated coverage of point-of-care diagnostics company, Talis Biomedical, (NASDAQ:TLIS) with a “buy” rating and $18 price target. The stock closed at $12.95 on March 8. “Consistent with our checks with KOLs … we...
Cantor Fitzgerald launched coverage of Akebia Therapeutics (NASDAQ:AKBA) with an “overweight” rating and $8 price target. The stock closed at $3.41 on March 5. The company’s lead asset, vadadustat, is an oral hypoxia...
BTIG initiated coverage of OncoSec Medical (NASDAQ:ONCS) with a “buy” rating and $10 price target. The stock closed at $5.23 on March 5. OncoSec is working to develop safe versions of the powerful immune stimulator...
Echelon Capital Markets initiated coverage of Diagnos (TSXV:ADK) with a “speculative buy” rating and price target of 85 cents (Canadian). The stock closed at 60 cents on March 4. ADK is a commercial-stage artificial...
Canaccord Genuity raised its price target for TransMedics (NASDAQ:TMDX) to $46 from $20, predicting 2021 would be transformational with two potential product approvals and a roll-out of an enhanced support model. The...
Maxim Group launched coverage of NLS Pharmaceutics AG (NASDAQ:NLSP) with a “buy” rating and $8 price target. The stock closed at $2.83 on March 2. NLS is developing Quilience for narcolepsy and Nolazol for ADHD; both...